Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Should l Buy IRIX?
Source: Newsfilter
DAME Trial Enrollment: Iridex Corporation announced the successful enrollment of the first patient in the DAME Trial, which aims to evaluate the efficacy and safety of adding subthreshold MicroPulse treatments to anti-VEGF therapy for patients with severe diabetic macular edema (DME) across 20 clinical sites in the UK.
Potential Impact on Treatment: The trial, led by Professor Noemi Lois, seeks to determine if the new treatment pathway could reduce the need for frequent anti-VEGF injections, potentially lowering costs and risks associated with current DME treatments while improving patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRIX
About IRIX
IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IRIDEX Corporation Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: IRIDEX reported total revenue of $14.7 million for Q4 2025, reflecting a 16% year-over-year increase, indicating sustained growth in core product lines, particularly in glaucoma and retina segments, which suggests strong market demand.
- Cost Control Initiatives: The company plans to achieve quarterly savings of $165,000 starting Q1 2026 by relocating certain administrative functions out of California, and expects to reduce annual fixed costs by approximately $600,000 through a planned headquarters relocation, further enhancing profitability.
- Strong Product Sales: In Q4, the glaucoma business sold 15,900 probes and 44 G6 systems, with total probe sales reaching 57,800 and system sales at 133 for the year, demonstrating the market acceptance and growth potential of the Cyclo G6 platform.
- Optimistic Future Outlook: IRIDEX expects 2026 revenue to range from $51 million to $53 million, excluding contributions from the Middle East, indicating a growth potential of 1% to 5%, with management expressing confidence in future cash flows and margin improvements.
See More
IRIDEX (IRIX) Q4 2025 Earnings Call Transcript
See More
IRIDEX Q4 Earnings Beat Expectations Despite Revenue Miss
- Earnings Performance: IRIDEX reported a Q4 GAAP EPS of -$0.01, beating expectations by $0.01, indicating a slight improvement in profitability despite missing revenue targets.
- Revenue Growth: Total revenue for 2025 reached $52.7 million, an 8% increase from $48.7 million in 2024, reflecting a stable growth trend in the market, particularly driven by the glaucoma product line.
- Product Sales: Revenue from the Cyclo G6® glaucoma product family was $13.8 million, up from $12.7 million in 2024, with sales of Cyclo G6® probes increasing from 55,400 to 57,800, demonstrating sustained demand for the products.
- Cost Control: The company reduced operating expenses by 22% compared to the previous year, which not only enhances overall profitability but also provides greater financial flexibility for future investments and expansions.
See More
IRIDEX CORP: OUTLOOK REFLECTS EFFECTS OF MIDDLE EAST CONFLICT ON PRODUCT DELIVERY SCHEDULES DUE TO MARKET DISRUPTIONS
Market Disruptions: IrideX Corp. is assessing the impact of market disruptions caused by ongoing conflicts in the Middle East.
Product Delivery Challenges: The conflicts are affecting product delivery timelines, leading to potential delays and complications in supply chains.
See More
IRIDEX REPORTS Q4 GROSS PROFIT OF $5.5 MILLION
- Financial Performance: IrideX reported a gross profit of $5.5 million for the fourth quarter.
- Market Impact: The financial results indicate a positive trend in the company's performance, potentially influencing investor confidence.
See More
Iridex's MicroPulse Technology Effectively Lowers Intraocular Pressure in Glaucoma Patients
- Clinical Study Results: An independent study at the University Eye Clinic Maastricht shows that retreatment with MicroPulse laser treatment (MicroPulse TLT) reduces intraocular pressure (IOP) by 25% to 35% in glaucoma patients, demonstrating the technology's effectiveness and safety in glaucoma management.
- Treatment Flexibility: The study involved 76 eyes, with retreatment timing varying from approximately 4 months to over 28 months, showcasing the individualized management capabilities of the technology, allowing for flexible treatment adjustments based on patient responses.
- Success Rate of Repeat Treatments: Results indicate that patients who initially benefited from treatment have higher long-term success rates upon retreatment, aiding clinicians in better identifying candidates for retreatment and optimizing glaucoma management strategies.
- Company Strategic Commitment: Iridex CEO Patrick Mercer stated that the findings further validate MicroPulse TLT as a valuable non-incisional option, reflecting the company's strong commitment to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.
See More
IRIDEX Corporation Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: IRIDEX reported total revenue of $14.7 million for Q4 2025, reflecting a 16% year-over-year increase, indicating sustained growth in core product lines, particularly in glaucoma and retina segments, which suggests strong market demand.
- Cost Control Initiatives: The company plans to achieve quarterly savings of $165,000 starting Q1 2026 by relocating certain administrative functions out of California, and expects to reduce annual fixed costs by approximately $600,000 through a planned headquarters relocation, further enhancing profitability.
- Strong Product Sales: In Q4, the glaucoma business sold 15,900 probes and 44 G6 systems, with total probe sales reaching 57,800 and system sales at 133 for the year, demonstrating the market acceptance and growth potential of the Cyclo G6 platform.
- Optimistic Future Outlook: IRIDEX expects 2026 revenue to range from $51 million to $53 million, excluding contributions from the Middle East, indicating a growth potential of 1% to 5%, with management expressing confidence in future cash flows and margin improvements.
See More
IRIDEX (IRIX) Q4 2025 Earnings Call Transcript
See More
IRIDEX Q4 Earnings Beat Expectations Despite Revenue Miss
- Earnings Performance: IRIDEX reported a Q4 GAAP EPS of -$0.01, beating expectations by $0.01, indicating a slight improvement in profitability despite missing revenue targets.
- Revenue Growth: Total revenue for 2025 reached $52.7 million, an 8% increase from $48.7 million in 2024, reflecting a stable growth trend in the market, particularly driven by the glaucoma product line.
- Product Sales: Revenue from the Cyclo G6® glaucoma product family was $13.8 million, up from $12.7 million in 2024, with sales of Cyclo G6® probes increasing from 55,400 to 57,800, demonstrating sustained demand for the products.
- Cost Control: The company reduced operating expenses by 22% compared to the previous year, which not only enhances overall profitability but also provides greater financial flexibility for future investments and expansions.
See More
IRIDEX CORP: OUTLOOK REFLECTS EFFECTS OF MIDDLE EAST CONFLICT ON PRODUCT DELIVERY SCHEDULES DUE TO MARKET DISRUPTIONS
Market Disruptions: IrideX Corp. is assessing the impact of market disruptions caused by ongoing conflicts in the Middle East.
Product Delivery Challenges: The conflicts are affecting product delivery timelines, leading to potential delays and complications in supply chains.
See More
IRIDEX REPORTS Q4 GROSS PROFIT OF $5.5 MILLION
- Financial Performance: IrideX reported a gross profit of $5.5 million for the fourth quarter.
- Market Impact: The financial results indicate a positive trend in the company's performance, potentially influencing investor confidence.
See More
Iridex's MicroPulse Technology Effectively Lowers Intraocular Pressure in Glaucoma Patients
- Clinical Study Results: An independent study at the University Eye Clinic Maastricht shows that retreatment with MicroPulse laser treatment (MicroPulse TLT) reduces intraocular pressure (IOP) by 25% to 35% in glaucoma patients, demonstrating the technology's effectiveness and safety in glaucoma management.
- Treatment Flexibility: The study involved 76 eyes, with retreatment timing varying from approximately 4 months to over 28 months, showcasing the individualized management capabilities of the technology, allowing for flexible treatment adjustments based on patient responses.
- Success Rate of Repeat Treatments: Results indicate that patients who initially benefited from treatment have higher long-term success rates upon retreatment, aiding clinicians in better identifying candidates for retreatment and optimizing glaucoma management strategies.
- Company Strategic Commitment: Iridex CEO Patrick Mercer stated that the findings further validate MicroPulse TLT as a valuable non-incisional option, reflecting the company's strong commitment to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.
See More
